Myelodysplastic syndrome treatment of.doc

 PAGE \* MERGEFORMAT 32 Myelodysplastic syndrome treatment of Keywords: Myelodysplastic Myelodysplastic syndrome (MDS) is an acquired stem cell disorder that can lead to ineffective hematopoiesis and peripheral blood cells decreased, there is development of acute myeloid leukemia (AML) trend. The etiology is unknown, both men and women the disease, more men than women, more common in 60 years of age or older [1], children seen in infancy to adolescence any age. Multi-MDS showed anemia, bleeding, fever, infection and liver enlargement of the spleen and blood as often as pancytopenia, also for one or two series of blood cells decreased, showing the performance of pathological blood, bone marrow proliferative activity or significantly more than active, a small number of cases may reduce the proliferation of [2  5]. Mainly rely on clinical diagnosis such as bone marrow and blood, if necessary, we can do bone marrow cell culture and cytogenetic examination. A classification France British Cooperative Group (FAB) according to the blood and bone marrow as the changes will be divided into five types of MDS: refractory anemia (RA), accompanied by ring sideroblastic refractory anemia (RAS), with the increase in primitive cells, refractory anemia (RAEB), changes in the MDS-RAEB refractory anemia (RAEB  T), chronic myelomonocytic leukemia (CMML). In children with, MDS is also common in patients with primary malignant tumor and accept a variety of treatment of patients. From the MDS transformed into AML accounts for about 15% of children with AML, MDS, but not the inevitable outcome of AML, especially in RA, RAS, CMML. The MDS transformed into AML with RAEB and RAEB  T more common [2  3]. 2 Treatment Present different types of MDS, using different therapeutic strategies. RA, RAS to anemia-based disease, use drugs to stimulate the bone marrow mainly be and to induce differentiation in the treatment; RAEB with sma